HU007 in Patients with Dry Eye Syndrome
Launched by HUONS CO., LTD. · Feb 22, 2023
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Age over 19
- • Corneal staining score(Oxford grading) ≥ 2 and Schirmer test ≤ 10mm/5min (If Schirmer test = 0mm/5min, Nasal stimulation schirmer test ≥ 3mm/5min) and TBUT test ≤10 in at least one of both eyes
- • Patients who have had more than one symptom of dry eye disease for at least 3 month before screening visit
- • Best corrected visual acuity of 0.2 or higher in both eyes
- • Those who voluntarily decided to participate and agreed in writing to comply with the precautions
- Exclusion Criteria:
- • Patients with clinically significant ocular disorders affected the test result
- • Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status
- • SBP ≥140mmHg or DBP ≥ 90mmHg or HbA1c \> 9%
- • Wearing contact lenses within 72 hr prior to screening visit or during clinical trial
- • Pregnancy or Breastfeeding
- • Patient with a history of glaucoma, or intraocular pressure of 25mmHg or higher at least one eyes
- • Patient with autoimmune disease (e.g. sjogren's syndrome)
- • Patients with a history of corneal transplant or neurotrophic keratitis
About Huons Co., Ltd.
Huons Co., Ltd. is a leading South Korean biopharmaceutical company dedicated to the research, development, and commercialization of innovative healthcare solutions. With a strong focus on advanced therapies and quality products, Huons specializes in areas such as injectable medications, biosimilars, and aesthetic treatments. The company is committed to enhancing patient outcomes through rigorous clinical trials and collaborations with global research institutions, striving to address unmet medical needs and improve the quality of life for patients worldwide. Huons continues to expand its portfolio and global presence, driven by a mission to contribute to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinju, , Korea, Republic Of
Jinju, , Korea, Republic Of
Patients applied
Trial Officials
Jun young Hyun
Principal Investigator
Seoul National University Bundang Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials